title: Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'.
authors.affiliation: International Drug Development Institute, Louvain-la-Neuve, Belgium Dendrix Research, Sao Paulo, Brazil everardo.saad@iddi.com.
authors.forename: E D
authors.initials: ED
authors.lastname: Saad
authors.affiliation: International Drug Development Institute, Louvain-la-Neuve, Belgium Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Hasselt University, Diepenbeek, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Buyse
mesh_terms: D000970:Antineoplastic Agents; D017277:Drug Approval; D006801:Humans
chemical_list: D000970:Antineoplastic Agents